Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA2/B7-H7

NCT05958199 is registered in ClinicalTrials.gov with NextPoint Therapeutics, Inc. as lead sponsor.

NCT NCT05958199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05958199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Lead sponsor
NextPoint Therapeutics, Inc.
Phase
Phase 1
Overall status
Suspended
Start date
July 21, 2023
Completion date
September 20, 2025
Enrollment
131 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm